The "Drug Production License" was approved, and the application for the production license of the first self-owned product - Eribulin mesylate injection was accepted by the State Medical Products Administration.
2022.12
The raw material of iodoxanol has passed the technical evaluation of the State Medical Products Administration (developed in cooperation with Bettel Pharmaceutical).
2022.11
Completed nearly 100 million yuan Pre-B round of financing, and launched the research and development of power coupling drugs
2022.10
SMP-100 innovative drug Australia and China clinical phase I completed
2022.8
Iodopropamine injection has been approved by the State Medical Products Administration (developed in cooperation with Bettel Pharmaceutical).
2021.8
Completed 90 million yuan A+ round of financing to accelerate the development of new drugs
2021.6
Kelingyuan Biotechnology (Shenzhen) Co., Ltd. was established in Shenzhen Pingshan Biomedical Innovation Industrial Park
2021.1
It won the title of "2020 Gazelle Enterprise of Sichuan Province" and entered the period of rapid development
2020.12
A round of financing of 50 million yuan completed
2019.10
Won the title of "high-tech enterprise"
2019.3
Won the title of "high-level Top Entrepreneurship Team in Sichuan Province"
2018.9
Won the title of "Chengdu Top Innovation and Entrepreneurship Team"
